Alzheimer's disease and amyloid β-peptide deposition in the brain: A matter of 'aging'?

Biochemical Society Transactions

Volumn 38, Issue 2, 2010, Pages 539-544

  Moro, Maria Luisa ^a,b   Collins, Matthew J ^a   Cappellini, Enrico ^a,c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Aging; Alzheimer's disease; Amyloid peptide; Isomerization; Protein misfolding; Racemization

Indexed keywords

AMYLOID BETA PROTEIN; ISOMERASE;

AGING; ALZHEIMER DISEASE; GENETIC SCREENING; HUMAN; ISOMERIZATION; PATHOGENESIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN AGING; PROTEIN FOLDING; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RACEMIZATION; SHORT SURVEY; SYNAPSE; ANIMAL; BIOLOGICAL MODEL; BIOLOGICAL RHYTHM; BRAIN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; REVIEW; TIME;

AGING; ALZHEIMER DISEASE; AMINO ACID ISOMERASES; AMYLOID BETA-PROTEIN; ANIMALS; BIOLOGICAL CLOCKS; BRAIN; HUMANS; MODELS, BIOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; TIME FACTORS;

EID: 77953254078     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0380539     Document Type: Short Survey

References (46)

1. Clarke, S. (2003) Aging as war between chemical and biochemical processes: protein methylation and the recognition of age-damaged proteins for repair. Ageing Res. Rev. 2, 263-285
2. Ritz-Timme, S. and Collins, M.J. (2002) Racemization of aspartic acid in human proteins, Ageing Res. Rev. 1, 43-59
3. Robinson, N.E. and Robinson, A.B. (2001) Molecular clocks. Proc. Natl. Acad. Sci. U.S.A. 98, 944-949
4. Robinson, N.E. and Robinson, A.B. (2001) Prediction of protein deamidation rates from primary and three-dimensional structure. Proc. Natl. Acad. Sci. U.S.A. 98, 4367-4372
5. Lowenson, J.D., Kim, E., Young, S.G. and Clarke, S. (2001) Limited accumulation of damaged proteins in L-isoaspartyl (D-aspartyl) O-methyltransferase-deficient mice. J. Biol. Chem. 276, 20695-20702
6. Reissner, K.J. and Aswad, D.W. (2003) Deamidation and isoaspartate formation in proteins: unwanted alterations or surreptitious signals? Cell. Mol. Life Sci. 60, 1281-1295
7. McCudden, C.R. and Kraus, V.B. (2006) Biochemistry of amino acid racemization and clinical application to musculoskeletal disease. Clin. Biochem. 39, 1112-1130
8. McFadden, P.N. and Clarke, S. (1987) Conversion of isoaspartyl peptides to normal peptides: implications for the cellular repair of damaged proteins. Proc. Natl. Acad. Sci. U.S.A. 84, 2595-2599
9. Lowenson, J.D. and Clarke, S. (1991) Structural elements affecting the recognition of L-isoaspartyl residues by the L-isoaspartyl/D-aspartyl protein methyltransferase: implications for the repair hypothesis. J. Biol. Chem. 266, 19396-19406
10. Lowenson, J.D. and Clarke, S. (1992) Recognition of D-aspartyl residues in polypeptides by the erythrocyte L-isoaspartyl/D-aspartyl protein methyltransferase: implications for the repair hypothesis. J. Biol. Chem. 267, 5985-5995
11. David, C.L., Orpiszewski, J., Zhu, X.-C., Reissner, K.J. and Aswad, D.W. (1998) Isoaspartate in chrondroitin sulfate proteoglycans of mammalian brain. J. Biol. Chem. 273, 32063-32070
12. Dehart, M.P. and Anderson, B.D. (2007) The role of the cyclic imide in alternate degradation pathways for asparagine-containing peptides and proteins. J. Pharm. Sci. 96, 2667-2685
13. Lu, K.P., Finn, G., Lee, T.H. and Nicholson, L.K. (2007) Prolyl cis-trans isomerization as a molecular timer. Nat. Chem. Biol. 3, 619-629
14. Alzheimer, A. (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych. Gerichtl. Med. 64, 177-179
15. Selkoe, D.J. (2004) Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 6, 1054-1061
16. Shankar, G.M., Leissring, M.A., Adame, A., Sun, X., Spooner, E., Masliah, E., Selkoe, D.J., Lemere, C.A. and Walsh, D.M. (2009) Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life. Neurobiol. Dis. 36, 293-302
17. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J. and Selkoe, D.J. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (Pubitemid 34288854)
18. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A. et al. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842
19. Roher, A.E., Lowenson, J.D., Clarke, S., Wolkow, C., Wang, R., Cotter, R.J., Reardon, I.M., Ziircher-Neely, H.A., Heinrikson, R.L., Ball, M.J. and Greenberg, B.D. (1993) Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 268, 3072-3083
20. Roher, A.E., Lowenson, J.D., Clarke, S., Woods, A.S., Cotter, R.J., Gowing, E. and Ball, M.J. (1993) β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90, 10836-10840
21. Shimizu, T., Matsuoka, Y. and Shirasawa, T. (2005) Biological significance of isoaspartate and its repair system. Biol. Pharm. Bull. 28, 1590-1596
22. Iwatsubo, T., Saido, T.C., Mann, D.M., Lee, V.M.-Y. and Trojanowski, J.Q. (1996) Full-length amyloid-β(1-42 (43)) and amino-terminally modified and truncated amyloid-β42(43) deposit in diffuse plaques. Am. J. Pathol. 149, 1823-1830
23. Mori, H., Ishii, K., Tomiyama, T., Furiya, Y., Sahara, N., Asano, S., Endo, N., Shirasawa, T. and Takio, K. (1994) Racemization: its biological significance on neuropathogenesis of Alzheimer's disease. Tohoku J. Exp. Med. 174, 251-262
24. Kuo, Y.-M., Webster, S., Emmerling, M.R., De Lima, N. and Roher, A.E. (1998) Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer's disease. Biochim. Biophys. Acta 1406, 291-298
25. 26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62, 248-59
26. Fisher, G.H., Payan, I.L., Chou, S.-J., Man, E.H., Cerwinski, S., Martin, T., Emory, C. and Frey Ii, W.H. (1992) Racemized D-aspartate in Alzheimer neurofibrillary tangles. Brain Res. Bull. 28, 127-131
27. Watanabe, A., Takio, K. and Ihara, Y. (1999) Deamidation and isoaspartate formation in smeared tau in paired helical filaments. J. Biol. Chem. 274, 7368-7378
28. Liou, Y.-C., Sun, A., Ryo, A., Zhou, X.Z., Yu, Z.-X., Huang, H.-K., Uchida, T., Bronson, R., Bing, G., Li, X. et al. (2003) Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424, 556-561 (Pubitemid 36975777)
29. Pastorino, L., Sun, A., Lu, P.-J., Zhou, X.Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.-H., Li, X. et al. (2006) The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production. Nature 440, 528-534
30. 23 residue affects the aggregation properties of Alzheimer amyloid β protein analogues. J. Biol. Chem. 269, 10205-10208
31. Orpiszewski, J., Schormann, N., Kluve-Beckerman, B., Liepnieks, J.J. and Benson, M.D. (2000) Protein aging hypothesis of Alzheimer disease. FASEB J. 14, 1255-1263 (Pubitemid 30350407)
32. Aswad, D.W. (ed.) (1995) Deamidation and Isoaspartate Formation in Peptides and Proteins, CRC Press, Boca Raton
33. 23 residue. Biochem. Biophys. Res. Commun. 364, 464-469
34. 23 of Aβ42 do not increase its aggregative ability, neurotoxicity, and radical productivity in vitro. Biochem. Biophys. Res. Commun. 366, 745-751
35. Wakutani, Y., Watanabe, K., Adachi, Y., Wada-Isoe, K., Urakami, K., Ninomiya, H., Saido, T.C., Hashimoto, T., Iwatsubo, T. and Nakashima, K. (2004) Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1039-1042
36. Boche, D. and Nicoll, J.A.R. (2008) The role of the immune system in clearance of Aβ from the brain. Brain Pathol. 18, 267-278
37. Miners, J.S., Baig, S., Palmer, J., Palmer, L.E., Kehoe, P.G. and Love, S. (2008) Aβ-Degrading enzymes in Alzheimer's disease. Brain Pathol. 18, 240-252
38. Mattson, M.P. (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639 (Pubitemid 39061671)
39. Gralle, M. and Ferreira, S.T. (2007) Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts. Prog. Neurobiol. 82, 11-32
40. Hook, V., Toneff, T., Bogyo, M., Greenbaum, D., Medzihradszky, K.F., Neveu, J., Lane, W., Hook, G. and Reisine, T. (2005) Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer's disease. Biol. Chem. 386, 931-940
41. Böhme, L., Hoffmann, T., Manhart, S., Wolf, R. and Demuth, H.-U. (2008) Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential β-secretases. Biol. Chem. 389, 1055-66
42. Böhme, L., Bär, J.W., Hoffmann, T., Manhart, S., Ludwig, H.-H., Rosche, F. and Demuth, H.-U. (2008) Isoaspartate residues dramatically influence substrate recognition and turnover by proteases. Biol. Chem. 389, 1043-1053
43. Fonseca, M.I., Head, E., Velazquez, P., Cotman, C.W. and Tenner, A.J. (1999) The presence of isoaspartic acid in β amyloid plaques indicates plaque age. Exp. Neurol. 157, 277-288
44. Velazquez, P., Cribbs, D.H., Poulos, T.L. and Tenner, A.J. (1997) Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat. Med. 3, 77-79
45. Sargaeva, N.P., Lin, C. and O'Connor, P.B. (2009) Identification of aspartic and isoaspartic acid residues in amyloid β peptides, including Aβ1-42, using electron-ion reactions. Anal. Chem. 81, 9778-9786
46. Sciarretta, K.L., Gordon, D.J., Meredith, S.C., Indu, K. and Ronald, W. (2006) Peptide-based inhibitors of amyloid assembly. Methods Enzymol. 413, 273-312